Entera Bio Ltd

Entera Bio operates with a market capitalization of $71.87 million and a price-to-book ratio of 5.49, indicating a premium valuation relative to its tangible book value. The company holds $7.11 million in cash and equivalents, while its total liabilities amount to $2.89 million, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 6.94, which suggests strong short-term liquidity. The company is currently unprofitable, with a net loss of $11.44 million and an operating loss of $11.53 million. Its return on equity is -87.31%, and return on assets is -71.53%, both significantly below industry norms for biotechnology firms. The enterprise value to revenue ratio of 1,542.05 reflects a high valuation relative to its current revenue of $42.00 million, which is driven by its early-stage development profile. Entera Bio's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's operations are entirely focused on the development of oral formulations of biologics, with no material revenue from other therapeutic areas or geographies. The company's growth trajectory is speculative, with no disclosed revenue growth in the current fiscal year. Analysts have assigned a mean price target of $9.00, implying a potential 567% upside from the current market price of $1.32. However, the absence of positive operating cash flow (-$7.37 million) and a free cash flow deficit of $11.52 million suggests that the company will require continued external financing to fund operations. Entera Bio faces low immediate liquidity and dilution risks, with no filing-based flags detected. The company has no long-term debt and a low dilution potential, as shares outstanding remain unchanged between basic and diluted counts. However, the absence of profitability and the high valuation multiple suggest that the company is dependent on capital markets for continued operations. No recent filings or transcripts have been disclosed that would indicate material changes in the company's business strategy or financial position. The company remains in the clinical development phase, with no commercial products currently generating revenue.